Thomson Reuters has acquired GeneGo, a provider of biology and disease information, analytics and decision support services for pharmaceutical research and development.
GeneGo, which is based in San Diego, will become part of the Healthcare & Science business of Thomson Reuters. Financial terms of the transaction were not disclosed.
Jon Brett-Harris, executive vice president at Thomson Reuters, said GeneGo's scientific expertise and assets in biology-driven drug discovery complement the Thomson Reuters life sciences portfolio that covers drug pipeline competitive intelligence, patents and chemistry.
"Thomson Reuters now provides comprehensive decision support solutions to help researchers striving to bring more effective medications to market," said Brett-Harris. "There is an increasing need for biology content, detailed disease insights and analytics to support R&D productivity and to enable a more personalized approach to medicine."
Thomson Reuters focused on GeneGo's capabilities in analytics, data management and value-added services and track record deploying decision support systems. The company is well known in the life sciences community for its MetaBase, a knowledge base in systems biology.